A site where you can find recommended contractors for non-clinical testing|effical " Non-Clinical CROs and Agencies " Porsolt

Porsolt

Porsolt is a global CRO based in France.We provide a broad range of contract services for non-clinical development, ranging from early drug discovery screening to pharmacology, safety evaluation, pharmacokinetics, and support toward regulatory submissions.The tests are conducted not by an agency, but by our own research facility and specialized staff.

Characteristics of Porsolt's non-clinical contract testing services

Efficacy evaluation and pharmacological testing for diverse disease areas

In Porsolt,Central nervous system, cardiovascular, inflammation, oncology, pain, respiratory, liver disease, metabolic disease, skin disease, etc.We support non-clinical research across a wide range of fields. Equipped with various evaluation systems including in vitro, ex vivo, in ovo, and in vivo, we conduct pharmacological studies using multiple animal species. We can develop testing systems tailored to your research objectives, ranging from early-stage drug discovery screening to the efficacy evaluation of candidate compounds.

Safety pharmacology and non-clinical studies compliant with GLP

In the safety evaluation,Pharmacological and toxicological tests compliant with GLPare being conducted. We support studies evaluating effects on the cardiovascular, central nervous, and respiratory systems as a core battery based on ICH S7. A wide range of evaluations from in vitro to in vivo is possible, including hERG channel assays, blood pressure, heart rate, and electrocardiogram measurements, as well as respiratory function evaluations. Porsolt has continuously maintained its GLP compliance status since passing a GLP compliance audit in 2000.

Supporting drug discovery and development from pharmacokinetics to regulatory submissions

Not only efficacy evaluation,pharmacokinetic study, formulation analysis, bioanalysis, toxicity evaluationWe also offer services such as pharmacokinetics using multiple animal species including mice, rats, dogs, and minipigs, with the capability to collect samples of blood, plasma, cerebrospinal fluid, and various tissues. In addition, we provide scientific support for regulatory submissions at each stage of non-clinical development.

参照元:Porsolt公式サイト
https://www.porsolt.com/

An example of a disease model owned by Porsolt

At Porsolt, we have developed various in vivo and in vitro models for each disease area. For example, in the oncology field,orthotopic and subcutaneous xenograft models targeting breast cancer, lung cancer, colorectal cancer, glioblastoma, etc.Supports drug efficacy evaluation using [X]. Models can be selected according to the disease and evaluation purpose.

参照元:Porsolt公式サイト
https://www.porsolt.com/

Porsolt preclinical study cases

2D・3Dモデルを用いた予測毒性評価

The Porsolt official website publishes papers and research results related to non-clinical research. For example,A study continuously evaluating drug withdrawal in rats using telemetryNow, we are measuring body temperature, amount of exercise, heart rate, mean arterial pressure, and other parameters over time. On the other hand, case studies summarizing the contents and results of trials commissioned by individual pharmaceutical companies are limited on our official website.

参照元:Porsolt公式資料 In Vitro Predictive Toxicity Screening Assays during Early Stage Drug Development: Case Study Data for the Validity of 2D and 3D Models
https://www.porsolt.com/wp-content/uploads/2023/Catalog/catalog_interactive_Porsolt.pdf

Porsolt's corporate information

参照元:Porsolt公式サイト
https://www.porsolt.com/
AddressZ.A. de Glatigné, 53940 Le Genest-Saint-Isle, France
Tel+33 2 43 69 36 07
Websitehttps://www.porsolt.com/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.

  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.

  • The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

By region
list of animal models
Expertise & Track Record
3 Recommended Contract Non-Clinical Testing Services